Accelero Biostructures

Executive Summary

Accelero Biostructures is a private San Francisco-based company that accelerates structure-based drug discovery by addressing bottlenecks in the gene-to-structure workflow. Leveraging high-throughput protein crystallography platforms, the company enables rapid determination of protein structures critical for biologics, antibody, and proteomics research. Founded in 2012, Accelero serves pharmaceutical and biotechnology clients seeking to expedite target identification and lead optimization. By continuously innovating its platform, the company aims to maintain best-in-class capabilities in structural biology. While details on funding and commercialization remain undisclosed, Accelero operates in the high-growth space of integrated structural biology services, competing with firms like XtalPi and ProteinQure. Its technology is particularly relevant for challenging targets such as membrane proteins and complexes, where speed and throughput are paramount. The company's focus on shortening the timeline from gene to structure positions it as a key enabler for next-generation drug development, especially in antibody engineering and rational drug design.

Upcoming Catalysts (preview)

• Q3 2026Major pharma partnership for platform licensing50% success
• Q2 2027Launch of next-generation high-throughput crystallography platform70% success
• Q1 2027Series C funding round exceeding $30M40% success